Skip to content
Improving Narcolepsy Therapy with Drug Delivery Technology episode artwork

Jul 23, 2020 21 min

Improving Narcolepsy Therapy with Drug Delivery Technology

from RARECast

Narcolepsy is a rare neurological sleep disorder with limited treatment options. Avadel is working on a controlled-release formulation of the standard of care, sodium oxybate, that allows for a once nightly dose of the drug. We spoke to Greg Divis, CEO of Avadel, about the company’s experimental therapy for narcolepsy, how it improves on the existing standard of care, and how it breaks with the company’s existing base of business. Editor's note: We recorded this podcast in late June. During the interview, Divis discussed the company's hospital products. On July 1, 2020, Avadel announced the sale of its hospital products portfolio to strategically focus on advancing FT218 through the FDA regulatory review process.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Improving Narcolepsy Therapy with Drug Delivery Technology

0:00 21:15

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 21 minutes long.

When was this RARECast episode published?

This episode was published on July 23, 2020.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.